Stay updated on Pemigatinib Dose-Escalation Clinical Trial
Sign up to get notified when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.

Latest updates to the Pemigatinib Dose-Escalation Clinical Trial page
- Check2 days agoChange DetectedLocations were added for AL, CA, CT, DC, FL, GA, MI, MO, NJ, NY, NC, OH, SC, and TX; the HHS Vulnerability Disclosure link was removed.SummaryDifference0.9%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedPublications section now states that entries are automatically filled from PubMed and may not all pertain to the study, and the page revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check39 days agoChange DetectedThe top funding-status notice regarding possible delays and NIH operations has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check60 days agoChange DetectedNo meaningful changes detected between the two screenshots of the Study Details page. The content and layout appear unchanged, including sections like Eligibility Criteria, Interventions, Primary and Secondary Outcomes, and Locations.SummaryDifference0.2%

- Check82 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference1%

- Check89 days agoChange DetectedUpdated disease naming from Plasma cell myeloma to Multiple myeloma and bumped the revision to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Pemigatinib Dose-Escalation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.